[Scope and limitations of acetylcholinesterase inhibitors].
[Scope and limitations of acetylcholinesterase inhibitors].
复制标题
[乙酰胆碱酯酶抑制剂的范围和局限性]。
DOI：
10.1254/fpj.124.163
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
H. Sugimoto
中科院分区：
文献类型：
--
作者：
H. Sugimoto
增强胆碱能神经元的活性被认为是治疗阿尔茨海默病（AD）最有前途的方法之一。多奈哌齐是一种具有代表性的乙酰胆碱酯酶抑制剂（AChEI），是AChEI类药物中最成功的一种。正在研究AChEI的其他作用机制，神经保护作用和烟碱受体增强作用。AD是一种神经退行性疾病，AChEI是一种有效的抗AD药物。AChEI能缓解AD的症状，延缓AD的进展，但不能治愈AD。然而，AChEI现在是用于其他疾病的广泛临床研究的主题，例如，其他类型的痴呆（如路易体病、脑血管性痴呆和帕金森病痴呆）和偏头痛。这些药物也正在研究作为联合治疗，例如，与抗氧化剂，SERM和NMDA拮抗剂。
Enhancement of the activity of cholinergic neurons has been regarded as one of the most promising methods for treating Alzheimer's disease (AD). Donepezil is a representative acetylcholinesterase inhibitor (AChEI) and is a great success among the AChEI drugs. AChEIs are being studied for other mechanisms of action, neuroprotective action, and nicotinic receptor enhancement. AD is a type of neurodegenerative disease and AChEIs have been found to be an effective anti-AD medication. AChEI can alleviate the symptoms and delay the progression of AD, but it cannot cure the disease. However, AChEIs are now the subject of a wide range of clinical studies for other diseases, for example, other types of dementia (such as Lewy body disease, cerebral vascular dementia, and Parkinson's disease dementia), and migraine. These drugs are also being studied as a combination therapy, for example, with an antioxidant, SERM, and NMDA antagonist.
影响因子：
120.7
作者：
Tariot, PN;Farlow, MR;Gergel, I
通讯作者：
Gergel, I